Abbvie Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/15/2026)
| Balance Sheet | Total Assets | 133,960,000,000.00 | ROE | -2.44 % |
| Balance Sheet | Total Equity | -3,270,000,000.00 | ROA | 3.15 % |
| Cashflow | Capital Expenditures | -1,214,000,000.00 | P/FCF | 28.49 |
| Cashflow | Free Cash Flow | 17,816,000,512.00 | – | – |
| Cashflow | Operating Cash Flow | 19,030,000,000.00 | P/CF | 26.67 |
| Income | Earnings per Share (diluted) | 2.36 | Div. Yield | 2.35 % |
| Income | Net Income | 4,186,000,000.00 | P/E | 120.12 |
| Income | Shares Outstanding | 1,790,680,000.00 | P/B | -155.24 |
| Income | Total Revenue | 61,160,000,000.00 | P/S | 8.30 |
Ratios calculated on: 10/14/2026
Company Description
AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.abbvie.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more